XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Equity
 3 Months Ended
Mar. 31, 2022
Stockholders' Equity Note [Abstract]  
Equity Equity
The following summarizes the changes in equity for the three months ended March 31, 2022 (dollars in thousands):
Common
stock		Additional
paid-in
capital		Accumulated
earnings
less
dividends		Accumulated
other
comprehensive
loss		Total stockholder's equityNoncontrolling interestsTotal
equity
Balance at December 31, 2021$1,398 $10,716,414 $240,821 $(26,106)$10,932,527 $566 $10,933,093 
Net income attributable to common stockholders— — 262,044 — 262,044 — 262,044 
Gain on cash flow hedges, net— — — 10,155 10,155 — 10,155 
Cash flow hedge losses reclassified to earnings— — — 1,013 1,013 — 1,013 
Change in redemption value of redeemable noncontrolling interest— — (43)— (43)— (43)
Noncontrolling interest distribution and income allocation— — — — — (10)(10)
Dividends declared to common stockholders ($1.59 per share)
— — (222,373)— (222,373)— (222,373)
Issuance of common stock, net of withholdings1 (14,263)(1,501)— (15,763)— (15,763)
Amortization of deferred compensation— 9,176 — — 9,176 — 9,176 
Balance at March 31, 2022$1,399 $10,711,327 $278,948 $(14,938)$10,976,736 $556 $10,977,292 
The following summarizes the changes in equity for the three months ended March 31, 2021 (dollars in thousands):
Common
stock		Additional
paid-in
capital		Accumulated
earnings
less
dividends		Accumulated
other
comprehensive
loss		Total stockholder's equityNoncontrolling interestsTotal
equity
Balance at December 31, 2020$1,395 $10,664,416 $126,022 $(40,250)$10,751,583 $591 $10,752,174 
Net income attributable to common stockholders— — 142,223 — 142,223 — 142,223 
Cash flow hedge losses reclassified to earnings— — — 2,367 2,367 — 2,367 
Change in redemption value of redeemable noncontrolling interest— — (273)— (273)— (273)
Noncontrolling interest distribution and income allocation— — — — — (16)(16)
Dividends declared to common stockholders ($1.59 per share)
— — (221,779)— (221,779)— (221,779)
Issuance of common stock, net of withholdings1 (14,037)958 — (13,078)— (13,078)
Amortization of deferred compensation— 7,286 — — 7,286 — 7,286 
Balance at March 31, 2021$1,396 $10,657,665 $47,151 $(37,883)$10,668,329 $575 $10,668,904 

As of March 31, 2022 and December 31, 2021, the Company's charter had authorized for issuance a total of 280,000,000 shares of common stock and 50,000,000 shares of preferred stock.

During the three months ended March 31, 2022, the Company:

i.issued 4,304 shares of common stock in connection with stock options exercised;
ii.issued 605 shares of common stock through the Company's dividend reinvestment plan;
iii.issued 132,135 shares of common stock in connection with restricted stock grants and the conversion of performance awards to shares of common stock;
iv.withheld 69,721 shares of common stock to satisfy employees' tax withholding and other liabilities; and
v.canceled 1,181 shares of restricted common stock upon forfeiture.

Deferred compensation granted under the Company's Second Amended and Restated 2009 Equity Incentive Plan (the "2009 Plan") during the three months ended March 31, 2022 is not reflected on the accompanying Condensed Consolidated Balance Sheets as of March 31, 2022, and will not be reflected until recognized as compensation cost.

In July 2020, the Company’s Board of Directors approved a stock repurchase program under which the Company may acquire shares of its common stock in open market or negotiated transactions up to an aggregate purchase price of $500,000,000 (the "2020 Stock Repurchase Program"). Purchases of common stock under the 2020 Stock Repurchase Program may be exercised at the Company’s discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements and other corporate liquidity requirements and priorities. The 2020 Stock Repurchase Program does not have an expiration date and may be suspended or terminated at any time without prior notice. During the three months ended March 31, 2022, the Company had no repurchases of shares under this program. As of March 31, 2022, the Company had $316,148,000 remaining authorized for purchase under this program.
In May 2019, the Company commenced a fifth continuous equity program ("CEP V") under which the Company may sell (and/or enter into forward sale agreements for the sale of) up to $1,000,000,000 of its common stock from time to time. Actual sales will depend on a variety of factors to be determined by the Company, including market conditions, the trading price of the Company's common stock and the Company's determinations of the appropriate funding sources. The Company engaged sales agents for CEP V who receive compensation of up to 1.5% of the gross sales price for shares sold. The Company expects that, if entered into, it will physically settle each forward sale agreement on one or more dates specified by the Company on or prior to the maturity date of that particular forward sale agreement, in which case the Company will receive aggregate net cash proceeds at settlement equal to the number of shares underlying the particular forward agreement multiplied by the forward sale price. However, the Company may also elect to cash settle or net share settle a forward sale agreement. In connection with each forward sale agreement, the Company will pay the forward seller, in the form of a reduced initial forward sale price, a commission of up to 1.5% of the sales prices of all borrowed shares of common stock sold. During the three months ended March 31, 2022, the Company had no sales under this program. In December 2021, the Company entered into a forward contract under CEP V to sell 68,577 shares of common stock for approximate proceeds of $16,000,000 net of offering fees and discounts and based on the initial forward price, with settlement of the forward contract to occur on one or more dates not later than December 31, 2022. The final proceeds will be determined on the date(s) of settlement after adjustments for the Company's dividends and a daily interest factor. As of March 31, 2022, the Company had $705,961,000 remaining authorized for issuance under CEP V, after consideration of the forward contract.